Related Experiment Video
Updated: Aug 11, 2026
Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
Published on: January 15, 2011
[A study about the ability of interleukin-2 production, interleukin-2 receptor expression by lymphocytes from
1Beijing Tuberculosis and Thoracic Tumor Research Institute.
Insights
Lymphocytes from lung cancer patients show significantly reduced Interleukin-2 (IL2) production and expression. This impairment may hinder the body's natural anti-tumor immune response.
Area of Science:
- Immunology
- Oncology
Background:
- Interleukin-2 (IL2) is crucial for immune responses.
- Dysregulation of IL2 pathways is implicated in various cancers.
Purpose of the Study:
- To investigate IL2 production, IL2 receptor expression, and lymphocyte proliferation in lung cancer patients.
- To assess the correlation between these immune parameters and lung cancer progression.
Main Methods:
- Studied lymphocytes from 48 primary lung cancer patients and 50 healthy controls.
- Stimulated lymphocytes with phytohemagglutinin (PHA) for 48 hours.
- Measured IL2 activity, IL2 receptor expression, and proliferative response.
Main Results:
- Lung cancer patients exhibited significantly reduced IL2 production (approx. 30% of controls).
- IL2 production further decreased with lung cancer progression.
- Lymphocyte IL2 receptor expression and proliferative response were also significantly diminished in patients.
Conclusions:
- Impaired IL2 production and IL2 receptor expression in lung cancer patients may compromise IL2-dependent anti-tumor immunity.
- These findings highlight potential immune deficits in lung cancer patients.
Abstract:
The ability of Interleukin-2 (IL2) production, IL2 receptors expression and proliferative response by lymphocytes from 48 patients with primary lung cancer and 50 normal controls were studied. The results indicated that after lymphocytes were stimulated with PHA for 48 hours, the IL2 activity produced by lymphocytes from lung cancer patients was significantly reduced, the mean IL2 activity was only about 30% of that of normal controls, with lung cancer progression, the lymphocytes IL2 production tended to be more depressed. The lymphocytes IL2 receptors expression and proliferative response in cancer patients were also significantly decreased. Our study suggested that impaired IL2 production and IL2 receptors expression by lymphocytes from lung cancer patients may depress the IL2 dependent anti-tumor reaction in vivo.
